Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center

EAST SETAUKET, NY , Oct. 09, 2018 -- (Healthcare Sales &Marketing Network) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety and therapeutic benefit of Lixte’s... Biopharmaceuticals, Oncology, FDA Lixte Biotechnology, protein phosphatases, Myelodysplastic Syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

(Josep Carreras Leukaemia Research Institute) Researchers from Josep Carreras Leukemia Research Institute participate in an international study that confirms for the first time that mutation of the two TP53 gene's copies is associated with a worse prognosis in myelodysplastic syndromes, a group of blood cancers a more frequent in elderly population. The results of this study have been published in Nature Medicine journal and represent an advance in the diagnosis and treatment of this type of hematological cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(Memorial Sloan Kettering Cancer Center) A large international study led by researchers at Memorial Sloan Kettering has immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome and acute myeloid leukemia.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
We compared the transplant outcomes between HID and MSD transplants for AML and MSD aged ≥50 years. The results showed that HID transplant is feasible and safe for elderly AML/MDS patients. AbstractAllogeneic hematopoietic stem cell transplantation (allo ‐HSCT) is a potentially curative therapeutic option for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Increasing data suggest that haploidentical donor (HID) transplantation achieve comparable outcomes with HLA‐matched sibling donor (MSD) in adult AML/MDS. This re trospective study compared the outcomes of AML or MDS patients age ...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Title: FDA Approves Oral Treatment for Myelodysplastic SyndromeCategory: Health NewsCreated: 7/8/2020 12:00:00 AMLast Editorial Review: 7/9/2020 12:00:00 AM
Source: MedicineNet Cancer General - Category: Cancer & Oncology Source Type: news
MDS is a heterogeneous disease with diverse clinical manifestations, and an effective prognostic evaluation tool for MDS patients is needed. To achieve more accurate prognosis assessment for Chinese MDS patients, here we examined several scoring systems and explored the implications of gene mutations. The prognostic conditions were stratified against three different score systems (International Prognostic Scoring System (IPSS), WHO Prognostic Scoring System (WPSS), and Revised International Prognostic Scoring System (IPSS-R)) were retrospectively applied to 110 de novo MDS patients in study cohort in our hospital and the p...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Conclusion: No statistically significant radiation associations were observed among 114,270 nuclear weapons test participants followed for up to 65 y. The 95% confidence limits were narrow and exclude mortality risks per unit dose that are two to four times those reported in other investigations. Significantly elevated SMRs were seen for mesothelioma and asbestosis, attributed to asbestos exposure aboard ships. PMID: 32602389 [PubMed - as supplied by publisher]
Source: International Journal of Radiation Biology - Category: Radiology Tags: Int J Radiat Biol Source Type: research
In conclusion, IGF‑IR may serve as a potential therapeutic target of MDS. PMID: 32583001 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Zhang M, Luo J, Luo X, Liu L Abstract As a member of the cancer-testis antigen family, sperm-associated antigen 6 (SPAG6) has been reported to be associated with the pathogenesis of myelodysplastic syndromes (MDS). Previous studies have demonstrated that SPAG6 is upregulated in bone marrow from patients with MDS and MDS-transformed acute myeloid leukemia and that knockdown of SPAG6 expression levels suppressed proliferation and promote apoptosis and differentiation in SKM-1 cells. However, the association between SPAG6 and autophagy in SKM-1 cells remains unclear. Hence, the aim of the present study was to...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
our M Abstract Microtransplantation (MT) is based on injection of HLA-mismatched G-CSF mobilized hematopoietic stem cells, in combination with chemotherapy but without use of conditioning regimen nor immunosuppressive drugs. As a result, a transient microchimerism is induced without engraftment. Its efficacy relies both on host immune system stimulation (recipient versus tumor) and on a graft versus tumor effect. Data are scarce and concern mostly Asian patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (HR-MDS). In comparison to conventional treatment without MT, higher complete rem...
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Marketing | Myelodysplastic Syndrome | Pharmaceuticals